Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: Neurobiol Dis. 2019 Dec 16;136:104712. doi: 10.1016/j.nbd.2019.104712

Fig. 5. Primary Neuron Immunotherapy Assay Reveals Differential Potency of α-Synuclein Antibodies to Prevent LB-Like Pathology.

Fig. 5.

(A) Examples of pS129 α-synuclein pathology (green) and NeuN (magenta) immunostaining following treatment of primary neurons with α-synuclein PFFs and the noted representative antibodies. Scale bar=50 μm. (B) Quantification of pS129 α-synuclein area/neuron number normalized to IgG-treated neurons. Antibodies had varying effects on α-synuclein pathology and are ranked from least to most effective. Twenty-one of the antibodies showed statistically-significant reductions in pathology (Kruskal-Wallis test with Dunn’s multiple comparisons test: *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001). N=6–20/condition. Error bars represent standard error.